Serum soluble Fas and Fas ligand (FasL) in primary Sjogren's syndrome

Grants

Funding Acknowledgements

The authors wish to thank the patients and healthy individuals for their participation. We also thank the clinical staff of the the Department of Rheumatology at TQEH and staff of the Immunology Department at Monash University, particularly those involved in biological samples and/or data collection, including Ms Emma Dunstan and Ms Susan Lester. The authors wish to thank the French Society of Rheumatology for its support.